Okamoto, Naoki
Inaguma, Daijo http://orcid.org/0000-0002-3977-5933
Hayashi, Hiroki
Koseki, Akira
Iwamori, Toshiya
Kudo, Michiharu
Yuzawa, Yukio
Funding for this research was provided by:
Kyowa Kirin
Article History
Received: 20 December 2021
Accepted: 1 February 2022
First Online: 1 March 2022
Declarations
:
: Honoraria (lecture fee): D. Inaguma received lecture fees from Kyowa Kirin Co., Ltd., Torii Pharmaceutical Co., Ltd., Kissei Pharmaceutical Co., Ltd., and Ono Pharmaceutical Co., Ltd. H Hayashi received a lecture fee from Otsuka Pharmaceutical Co., Ltd. Grants received: D. Inaguma received research funding from Sanwa Kagaku Kenkyusho Co., Ltd. Y. Yuzawa received research grants from Otsuka Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd.
: The present study was conducted in accordance with the Ethical guidelines for Clinical Research by the Japanese Ministry of Health, Labor, and Welfare (created July 30, 2003; full revision December 28, 2004; full revision July 31, 2008) and the Helsinki Declaration (revised 2013). This study was approved by the clinical research ethics committee at Fujita Health University School of Medicine (approval number: HM19-157). All data were fully anonymized before the analysis.
: The contents of the entire research have been displayed in the information disclosure document on the Web, and informed consent was obtained in the form of an opt-out on the website. Those who were rejected were excluded. The trial registration number of the study was UMIN 000037476, and it was registered on August 1, 2019.